News and Announcements
Intermin Aquired the Anthill Gold Project
- Published March 08, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Intermin Resources Limited (ASX:IRC) is pleased to announce the execution of a binding agreement with Echo Resources Ltd (ASX:EAR) to acquire 100% of the Anthill gold project located 54km northwest of Kalgoorlie-Boulder in Western Australia.
KEY TAKEAWAYS:
- Binding Agreement executed with Echo Resources for 100% of the Anthill project;
- Project located within the Zuleika shear zone 54km northwest of Kalgoorlie-Boulder in Western Australia and 10km southeast of Intermin’s 100% owned Blister Dam project;
- Anthill has a quoted Resource Estimate (JORC 2004) of 160,000 ounces1 (Notes A and B);
- Consideration of $300,000 cash plus a capped production royalty;
- Historic drilling produced high grade results (Note C);
- Project area open along strike and at depth;
- Database review commenced with further drilling expected in the June Quarter.
Intermin is a gold exploration and mining company focussed on the Kalgoorlie and Menzies areas of Western Australia which are host to some of Australia’s richest gold deposits. The Company’s flagship projects are the 100% owned Menzies and Teal projects which host significant mineralisation and have the potential to be mined via open cut and underground methods.
Perth and Menzies-based Intermin is aiming to significantly grow its JORC-Compliant Mineral Resources, complete definitive feasibility studies on core projects and build a sustainable development pipeline.
Intermin is targeting the definition of significant high grade open cut and underground gold deposits, has acquired highly prospective tenure and will continue to actively pursue consolidation and value-adding joint venture opportunities for the benefit of all stakeholders.
For more information, please click below.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
